Group 1 - On November 17, Samsung Medical experienced a decline of 2.46% with a trading volume of 472 million yuan, and the net financing buy was -41.71 million yuan [1] - As of November 17, the total financing and securities lending balance for Samsung Medical was 308 million yuan, with a financing balance of 304 million yuan, accounting for 0.84% of the circulating market value [1] - The company’s main business revenue composition includes 79.70% from the power sector, 19.15% from medical services, and 1.15% from other businesses [1] Group 2 - As of September 30, the number of shareholders for Samsung Medical increased by 15.72% to 33,500, while the average circulating shares per person decreased by 13.94% to 41,941 shares [2] - For the period from January to September 2025, Samsung Medical reported a revenue of 11.08 billion yuan, representing a year-on-year growth of 6.19%, while the net profit attributable to the parent company was 1.528 billion yuan, a decrease of 15.85% year-on-year [2] Group 3 - Since its A-share listing, Samsung Medical has distributed a total of 6.407 billion yuan in dividends, with 3.329 billion yuan distributed in the last three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Samsung Medical, holding 51.056 million shares, an increase of 3.0756 million shares compared to the previous period [3]

Group 1 - Samsung Medical experienced a 5% decline in stock price, trading at 27.34 CNY per share, with a total transaction volume of 676 million CNY and a turnover rate of 1.71%, resulting in a total market capitalization of 38.418 billion CNY [1] - The company, Ningbo Samsung Medical Electric Co., Ltd., was established on February 1, 2007, and listed on June 15, 2011. Its main business involves the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1] - The revenue composition of Samsung Medical includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses, with no revenue from financing leasing and consulting services [1] Group 2 - Citic Prudential Fund has one fund heavily invested in Samsung Medical, specifically the Citic Prudential Emerging Industries Mixed A Fund (000209), which held 2.5721 million shares in the third quarter, unchanged from the previous period, accounting for 3.3% of the fund's net value [2] - The Citic Prudential Emerging Industries Mixed A Fund was established on July 17, 2013, with a latest scale of 1.839 billion CNY. Year-to-date returns are 30.86%, ranking 2777 out of 8147 in its category, while the one-year return is 19.45%, ranking 3450 out of 8056 [2] - The fund manager, Sun Haozhong, has been in the position for 5 years and 325 days, with a total asset scale of 3.145 billion CNY. The best fund return during his tenure is 77.62%, while the worst return is -55% [3]

Core Viewpoint - Samsung Medical's stock has experienced fluctuations, with a year-to-date decline of 9.68% but a recent recovery of 18.47% over the last five trading days [1] Group 1: Financial Performance - For the period from January to September 2025, Samsung Medical reported a revenue of 11.08 billion, representing a year-on-year growth of 6.19%, while the net profit attributable to shareholders decreased by 15.85% to 1.528 billion [2] - The company has distributed a total of 6.407 billion in dividends since its A-share listing, with 3.329 billion distributed over the last three years [3] Group 2: Stock Market Activity - As of November 7, Samsung Medical's stock price was 26.55, with a trading volume of 570 million and a turnover rate of 1.50%, leading to a total market capitalization of 37.308 billion [1] - The stock has seen significant net outflows of 34.124 million from main funds, with large orders buying 138 million and selling 127 million [1] Group 3: Business Overview - Samsung Medical, established on February 1, 2007, and listed on June 15, 2011, primarily engages in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment [2] - The company's revenue composition includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other business activities [2]

Core Viewpoint - Samsung Medical is a leading provider in the energy metering and medical services sector, with significant technological strength in power grid equipment, and has shown strong revenue and profit performance in the industry [1][2]. Group 1: Business Performance - In Q3 2025, Samsung Medical achieved a revenue of 11.08 billion, ranking second among 26 companies in the industry, with the top company, Chint Electric, reporting a revenue of 46.396 billion [2]. - The company's net profit for the same period was 1.507 billion, also placing it second in the industry, while Chint Electric's net profit was 5.656 billion [2]. Group 2: Financial Ratios - As of Q3 2025, Samsung Medical's debt-to-asset ratio was 47.57%, an increase from 44.26% in the previous year and above the industry average of 40.49% [3]. - The company's gross profit margin for Q3 2025 was 28.46%, down from 36.21% year-on-year but still higher than the industry average of 23.98% [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 15.72% to 33,500, while the average number of circulating A-shares held per shareholder decreased by 13.94% to 41,900 [5]. - The fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 51.056 million shares, an increase of 3.0756 million shares from the previous period [5]. Group 4: Order Backlog and Market Outlook - As of Q3 2025, the total order backlog for Samsung Medical reached 17.914 billion, a year-on-year increase of 14.69%, with overseas distribution orders at 2.169 billion, up 125.45% [5][6]. - The company is expected to see a recovery in its medical business, with a projected increase in the average price of domestic electric meters by 20-30% [6].

Group 1 - On October 15, Samsung Medical's stock rose by 2.07%, with a trading volume of 555 million yuan [1] - The financing data shows that on the same day, Samsung Medical had a financing purchase amount of 54.05 million yuan and a net financing purchase of 9.43 million yuan [1] - As of October 15, the total balance of margin trading for Samsung Medical was 375 million yuan, with a financing balance of 372 million yuan, accounting for 1.01% of the circulating market value [1] Group 2 - As of June 30, the number of shareholders of Samsung Medical increased to 29,000, a rise of 76.91%, while the average circulating shares per person decreased by 43.15% to 48,732 shares [2] - For the first half of 2025, Samsung Medical achieved an operating income of 7.972 billion yuan, a year-on-year increase of 13.93%, and a net profit attributable to the parent company of 1.230 billion yuan, up 6.93% year-on-year [2] Group 3 - Samsung Medical has distributed a total of 6.407 billion yuan in dividends since its A-share listing, with 3.329 billion yuan distributed in the last three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Samsung Medical, holding 47.9803 million shares, an increase of 3.9134 million shares compared to the previous period [3]

Core Viewpoint - Samsung Medical's stock experienced a slight decline of 0.37% on September 29, with a trading volume of 576 million yuan, indicating a mixed market sentiment towards the company [1]. Financing Summary - On September 29, Samsung Medical had a financing buy-in amount of 56.18 million yuan, with a net financing purchase of 10.93 million yuan after repayments [1]. - The total financing and securities balance for Samsung Medical reached 377 million yuan, with the financing balance accounting for 1.09% of the circulating market value, indicating a high level compared to the past year [1]. - The company had a low short-selling balance of 2.02 million yuan, with a short-selling volume of 3,800 shares on the same day [1]. Business Performance - As of June 30, Samsung Medical reported a total of 29,000 shareholders, an increase of 76.91% from the previous period, while the average circulating shares per person decreased by 43.15% to 48,732 shares [2]. - For the first half of 2025, Samsung Medical achieved an operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%, and a net profit attributable to shareholders of 1.230 billion yuan, up 6.93% year-on-year [2]. Dividend Information - Since its A-share listing, Samsung Medical has distributed a total of 5.728 billion yuan in dividends, with 2.650 billion yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Samsung Medical, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3].

Company Overview - SamSung Medical is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011. The company specializes in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1]. Financial Performance - For the first half of 2025, SamSung Medical achieved operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%. The net profit attributable to the parent company was 1.230 billion yuan, an increase of 6.93% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 5.728 billion yuan in dividends, with 2.650 billion yuan distributed over the past three years [3]. Stock Performance - As of September 22, SamSung Medical's stock price was 22.49 yuan per share, with a market capitalization of 31.603 billion yuan. The stock has declined by 24.72% year-to-date and has seen a slight decrease of 0.79% over the past five trading days [1]. - The company has a total of 29,000 shareholders as of June 30, with an average of 48,732 circulating shares per shareholder, a decrease of 43.15% from the previous period [2]. Shareholder Composition - As of June 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3]. Business Segmentation - The main business revenue composition of SamSung Medical includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses. The company is categorized under the electric equipment industry, specifically in power grid equipment and distribution equipment [1].

Company Overview - Samsung Medical is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011. The company specializes in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1]. Financial Performance - For the first half of 2025, Samsung Medical achieved operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%. The net profit attributable to the parent company was 1.230 billion yuan, an increase of 6.93% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 5.728 billion yuan, with 2.650 billion yuan distributed over the past three years [3]. Stock Performance - As of September 18, Samsung Medical's stock price decreased by 2.02%, trading at 22.75 yuan per share, with a total market capitalization of 31.969 billion yuan. The stock has declined by 23.85% year-to-date [1]. - The stock's trading volume showed a net inflow of 4.8744 million yuan from main funds, with significant buying and selling activities recorded [1]. Shareholder Information - As of June 30, the number of shareholders increased to 29,000, up by 76.91%, while the average circulating shares per person decreased by 43.15% to 48,732 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3]. Business Segmentation - The company's main business revenue composition includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses, with no revenue from financing leasing and consulting services [1]. - Samsung Medical is categorized under the electric equipment industry, specifically in the distribution equipment sector, and is associated with concepts such as private hospitals, mid-cap stocks, electric IoT, industrial internet, and energy storage [1].

Company Overview - Samsung Medical is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011. The company specializes in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1]. Financial Performance - For the first half of 2025, Samsung Medical achieved operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%. The net profit attributable to the parent company was 1.230 billion yuan, an increase of 6.93% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 5.728 billion yuan, with 2.650 billion yuan distributed over the past three years [3]. Stock Performance - As of September 17, Samsung Medical's stock price was 22.98 yuan per share, with a market capitalization of 32.292 billion yuan. The stock has decreased by 23.08% year-to-date but has seen a slight increase of 1.01% over the last five trading days [1]. - The company experienced a net inflow of main funds amounting to 5.7457 million yuan, with significant buying and selling activity from large orders [1]. Shareholder Information - As of June 30, the number of shareholders for Samsung Medical reached 29,000, an increase of 76.91% from the previous period. The average circulating shares per person decreased by 43.15% to 48,732 shares [2]. - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3]. Business Segmentation - The company's main business revenue composition includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses, with no revenue from financing leasing and consulting services [1]. - Samsung Medical operates within the electric equipment industry, specifically in the distribution equipment sector, and is associated with concepts such as private hospitals, mid-cap companies, industrial internet, electric power IoT, and charging piles [1].

Core Insights - Samsung Medical experienced a stock decline of 0.34% on August 25, with a trading volume of 991 million yuan [1] - The company reported a financing buy-in of 139 million yuan and a repayment of 110 million yuan on the same day, resulting in a net financing buy of 29.26 million yuan [1] - As of August 25, the total financing and securities lending balance for Samsung Medical was 492 million yuan, with a financing balance of 489 million yuan, accounting for 1.49% of the circulating market value, indicating a high level compared to the past year [1] Financing and Securities Lending - On August 25, Samsung Medical had a securities lending repayment of 300 shares and sold 19,100 shares, amounting to 445,600 yuan based on the closing price [1] - The remaining securities lending volume was 127,500 shares, with a balance of 2.97 million yuan, which is below the 30th percentile of the past year, indicating a low level [1] Company Overview - Samsung Medical Electric Co., Ltd. is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011 [1] - The company's main business includes the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1] - The revenue composition of Samsung Medical is as follows: smart distribution and utilization of electricity 76.16%, medical services 22.31%, other (supplementary) 1.48%, and financing leasing and consulting services 0.04% [1] Financial Performance - As of June 30, the number of shareholders for Samsung Medical reached 29,000, an increase of 76.91% compared to the previous period [2] - The average circulating shares per person decreased by 43.15% to 48,732 shares [2] - For the first half of 2025, Samsung Medical achieved an operating income of 7.972 billion yuan, a year-on-year increase of 13.93%, and a net profit attributable to shareholders of 1.230 billion yuan, up 6.93% year-on-year [2] Dividend Distribution - Since its A-share listing, Samsung Medical has distributed a total of 5.728 billion yuan in dividends, with 2.650 billion yuan distributed over the past three years [2] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder of Samsung Medical, holding 47.9803 million shares, an increase of 3.9134 million shares compared to the previous period [2]